일본과 해외의 조사회사나 출판사로부터 출판된 산업 조사 보고서 및 데이터 판매 · 연간 서비스 · 맞춤 정보 제공 ChosaReport-Korea 주식회사 SEMABIZ

e파머시(ePharmacy)의 중요 동향, 지역별 분석, 시장 예측 2022-2027년

출판:Juniper Research(주니퍼 리서치) 출판년도:2022년10월

ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027
세계의 e파머시(온라인 약국)를 조사해 시장 기회, 기술, 주요 촉진 요인, 주요 e파머시 벤더 15사 정보에 ​​관한 분석·해설을 실시

가격 GBP2,990
구성 영문조사보고서

자세한 것은 여기를 참고해 주세요。

리포트목차    주문/문의    조사회사/구입안내

Sample Request

Juniper Research「e파머시의 중요 동향, 지역별 분석, 시장 예측 2022-2027년 – ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027」는 세계의 e파머시(온라인 약국)를 조사해 시장 기회, 기술, 주요 촉진 요인, 주요 e파머시 벤더 15사 정보에 ​​관한 분석·해설을 실시하고 있습니다.

또한 e파머시 이용자수, 전자파머시 거래수, OTC수, 전자파머시 경유 처방전 거래수, e파머시 총수익에 대해서는 세계 60개국의 예측을 포함한 시장 데이터도 제공합니다.

Juniper Research「e파머시의 중요 동향, 지역별 분석, 시장 예측 2022-2027년 - ePharmacy: Key Trends, Regional Analysis and Market Forecasts 2022-2027」는 세계의 e파머시(온라인 약국)를 조사해 시장 기회, 기술, 주요 촉진 요인, 주요 e파머시 벤더 15사 정보에 ​​관한 분석·해설을 실시하고 있습니다.

주요 게시물

  • 시장 역학
    • 신형 코로나 바이러스 감염(COVID-19)이 제공하는 시장에 미치는 영향
    • e 파머시의 향후 전략적 방향과 시장 전망
    • 규제 및 데이터 공유에 주목해야 할 주요 문제점
  • 지역별 분석: 주요 8개 지역 16개국에서 e-Pharmacy의 현재 배포 수준과 향후 전망
  • 주요 조사 결과 및 전략적 제안
  • 산업 예측 : e-Pharmacey의 사용자, e-Pharmacey에 대한 연간 지출 총액, e-Pharmacey의 총 과금 수익, e-Pharmacey의 총 거래 금액의 예측. OTC 및 처방전 의약품 당 총 거래 수와 수익. 대상지역(8지역) 및 국가(60개국)는 다음과 같습니다.
    • 북미: 캐나다, 미국
    • 라틴 아메리카: 아르헨티나, 브라질, 칠레, 콜롬비아, 에콰도르, 멕시코, 페루, 우루과이
    • 서유럽: 오스트리아, 벨기에, 덴마크, 핀란드, 프랑스, ​​독일, 그리스, 아일랜드, 이탈리아, 네덜란드, 노르웨이, 포르투갈, 스페인, 스웨덴, 스위스, 영국
    • 중동유럽: 크로아티아, 체코, 헝가리, 폴란드, 루마니아, 러시아, 터키, 우크라이나
    • 극동과 중국: 중국, Hong Kong, 일본, 한국
    • 인도 아대륙: 방글라데시, 인도, 네팔, 파키스탄
    • 기타 아시아 태평양 지역: 호주, 인도네시아, 말레이시아, 뉴질랜드, 필리핀, 싱가포르, 태국, 베트남
    • 아프리카 및 중동: 알제리, 이집트, 이스라엘, 케냐, 쿠웨이트, 나이지리아, 카타르, 사우디 아라비아, 남아프리카, 아랍 에미리트
  • Juniper Research의 경쟁 스코어보드 : 주요 15개 기업의 특성과 능력 평가
    • 1mg
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Health
    • DocMorris
    • Express Scripts
    • Giant Eagle Pharmacy
    • Kroger
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

이 보고서는 다음 질문에 대한 답변으로 이어지는 정보를 제공합니다.

  1. 주요 시장 동향이 ePharmacy에 어떤 영향을 미치는가?
  2. e Pharmacey는 OTC와 처방전 의약품과 어떤 차이가 있는가?
  3. ePharmacy 시장의 주요 벤더는?
  4. ePharmacy에 있어서 성장 저해 요인이 되는 한계는?
  5. ePharmacy가 가장 성공하는 지역은?

Report Overview

Juniper Research’s ePharmacy report provides a detailed evaluation of the market, including the adoption of ePharmacy within both developing and established markets. In addition, this report covers market opportunities; providing strategic insights into the technologies and key drivers that are pushing the space forward, and the role of 15 leading ePharmacy vendors across the market.

The research suite also contains a detailed dataset; providing forecasts for 60 countries across a number of different metrics, including the number of ePharmacy users, number of ePharmacy transactions, number of OTC (Over the Counter) and prescription transactions through ePharmacy and total ePharmacy revenue.

This research suite comprises of:

  • Strategy & Forecasts (PDF)
  • 5-year Market Sizing & Forecast Spreadsheet (Excel)
  • 12 Months Access to harvest Online Data Platform

KEY FEATURES

  • Market Dynamics: A strategic analysis of the major drivers, challenges, and innovations shaping the adoption and development of ePharmacy technologies, including the following:
    • COVID-19 impact on the ePharmacy market
    • Future strategic direction and market outlook for ePharmacy
    • Key issues ePharmacy vendors must be aware of surrounding legislation and data sharing
  • Regional Analysis: A regional-level analysis of 16 countries, spanning 8 key regions; covering the current deployment level and future outlook of ePharmacy in each market.
  • Key Takeaways & Strategic Recommendations: Analysis of key development opportunities within ePharmacies, accompanied by key strategic recommendations for stakeholders.
  • Benchmark Industry Forecasts: Includes forecasts for total number of ePharmacy users, total annual spend on ePharmacy, total fee revenue from ePharmacy, total transaction value from ePharmacy. Total number of transactions and revenue split by OTC and prescription medication. This data is split by our 8 key forecast regions and 60 countries:
    • North America:
      • Canada, US
    • Latin America:
      • Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
    • West Europe:
      • Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK
    • Central & East Europe:
      • Croatia, Czech Republic, Hungary, Poland, Romania, Russia, Turkey, Ukraine
    • Far East & China:
      • China, Hong Kong, Japan, South Korea
    • Indian Subcontinent:
      • Bangladesh, India, Nepal, Pakistan
    • Rest of Asia Pacific:
      • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
    • Africa & Middle East:
      • Algeria, Egypt, Israel, Kenya, Kuwait, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates
  • Juniper Research Competitor Leaderboard: Key player capability and capacity assessment for 15 ePharmacy vendors:
    • 1mg
    • Amazon Pharmacy
    • Apollo Pharmacy
    • CVS Health
    • DocMorris
    • Express Scripts
    • Giant Eagle Pharmacy
    • Kroger
    • Lloyds Pharmacy
    • Netmeds
    • Optum
    • Rowlands Pharmacy
    • Walgreens Boots Alliance
    • Walmart
    • Well Pharmacy

KEY QUESTIONS ANSWERED

  1. How will key market trends affect ePharmacy?
  2. How will ePharmacy differ for over-the-counter and prescription medication?
  3. Who are the leading vendors in the ePharmacy market?
  4. What limitations are holding back ePharmacy?
  5. What regions will ePharmacy be most successful in?

COMPANIES REFERENCED

Included in the Juniper Research Competitor Leaderboard: 1mg, Amazon Pharmacy, Apollo Pharmacy, CVS Health, DocMorris, Express Scripts, Giant Eagle, Lloyds Pharmacy, Netmeds, Optum, Rowlands Pharmacy, The Kroger, Walgreens Boots Alliance, Walmart, Well Pharmacy.

Mentioned: Accredo, Adipositas Care, Adobe, Aetna, Bajaj Allianz, Bakers, Berkshire Hathaway, Blue Cross Blue Shield, Braze, CareCentrix, CareContinum, CareZone, Chefaa, City Market Food and Pharmacy, Copps, CuraScriptSD, Deliveroo, Ecrebo, Epic, Evicore Healthcare, Famhealth, FredMeyer, Freedom Fertility Pharmacy, Frys, HasHealth, Haven, HDFC, Horizon, ICICI Bank, Inside Rx, JPMorgan Chase, KiviHealth, Lazada Philippines, Lyf, Mamajan Imaging, Max Bupa, MedAvail, Medbase, Mesmerize, Microsoft, MyMatrixx, NCotably, Novo Nordisk, Omnicell, Onofre, Patanjali, PathCare, PAYBACK, PillPack, Practio, Prime Therapeutics, Raia Drogasil SA, SBI, Shopee Philippines, Signify Health, Target Pharmacies, Tata Digital, TeleClinic, Thyrocare, Verizon, Willons, Yodawy, ZEE5, Zur Rose Group.

DATA & INTERACTIVE FORECAST

Juniper Research’s ePharmacy forecast suite includes:

  • Prescription Medication
  • Over-the-Counter Medication

Metrics including total number of transactions completed through ePharmacy, total annual spend on ePharmacy, total revenue through ePharmacy transactions, total revenue through ePharmacy fees, split by OTC and prescription medication.

Geographical splits: 60 countries
Number of tables: Over 31 tables
Number of datapoints: Over 23,500 datapoints

harvest: Our online data platform, harvest, contains the very latest market data and is updated throughout the year. This is a fully featured platform enabling clients to better understand key data trends and manipulate charts and tables; overlaying different forecasts within the one chart – using the comparison tool. Empower your business with our market intelligence centre, and receive alerts whenever your data is updated.

Interactive Excels (IFxl): Our IFxl tool enables clients to manipulate both forecast data and charts, within an Excel environment, to test their own assumptions using the interactive scenario tool and compare selected markets side by side in customised charts and tables. IFxls greatly increase a client’s ability to both understand a particular market and to integrate their own views into the model.

FORECAST SUMMARY

The number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases through refining the efficiency and simplicity that ePharmacy provides.

  • Consumers will continue to utilise ePharmacies as they realise the benefits it provides them, including affordability of medication, and a wider range of choice compared to bricks-and-mortar pharmacies.
  • ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of their prescriptions.
  • ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027, accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

보고서 구성 및 가격표

  • 시장 동향, 전략, 예측 보고서(PDF)
    Market trends, strategies and forecasts report (pdf)
  • 시장 데이터 및 예측(Excel)
    Market data & forecasts – All topic data and interactivity (xls)
  • 최신 데이터에 대한 12개월 액세스
    harvest market data platform (12 months’ online access)
GBP 2,990

[보도자료] EPHARMACY USERS TO REACH 1 BILLION GLOBALLY BY 2027; CAPITALISING ON COVID-19 SURGE

Hampshire, UK – 10th October 2022: A new study from Juniper Research found that the number of ePharmacy users will reach 1 billion globally by 2027; increasing from 795 million in 2022, a growth of 28%. The research identified this increase as the culmination of surging adoption resulting from the COVID-19 pandemic, where consumers were unable to leave their homes and turned to receiving medication through ePharmacies. Growth will continue, as vendors focus on retaining and expanding their customer bases by refining the efficiency and simplicity that ePharmacy provides.

ePharmacy is where online pharmacies sell medication, including prescriptions, over the Internet, with the ability to deliver straight to the consumer.

Increase in Accessibility of eCommerce Driving Growth

The research predicts that consumers will continue to utilise ePharmacies as they realise the benefits they provide them, including affordability of medication, and a wider range of choice compared to bricks‑and-mortar pharmacies.

Furthermore, the report predicts that ePharmacy growth will be sustained by simplifying the online process. This can be achieved through more widespread acceptance of ePrescriptions; eliminating paper copies of prescriptions.

Research author Cara Malone remarked: “ePharmacy vendors have the ability to further simplify the process through the use of solutions, including consumers receiving their prescribed medication, sorted into daily pouches containing information regarding dosage, date and time to be taken.”

Issues Surrounding Delivery Remain a Barrier

The research anticipates that ePharmacy services will continue to be predominantly utilised for OTC (Over-the-Counter) medication. OTC transactions will reach 8.9 billion globally in 2027; accounting for 64% of total global transaction value. This is compared to 5 billion prescription transactions globally in the same year. Prescription digitisation will lag behind due to consumer concerns around delivery accuracy, timing and missed deliveries. In order to allay these concerns and offset the abundance of illegitimate ePharmacies, real-time tracking and stronger regulations for ePharmacies should be priorities to secure future growth.

Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports, and industry commentary.


목차

Contents

1. Key Takeaways & Strategic Recommendations

1.1 Key Takeaways & Strategic Recommendations ………6
1.2 Strategic Recommendations …………….7

2. Current Status & Future Outlook

2.1 Overview of ePharmacy Ecosystem ………….9
Figure 2.1: Visualisation Showing ePharmacy Stages ……..9
2.1.1 Types of ePharmacy…………….9
i. Digital-only Stores …………..9
ii. Digital Twin of Bricks-and-Mortar…………9
2.1.2 ePrescribing ……………..9
Figure 2.2: Visualisation of ePrescribing………… 10
2.2 Benefits of ePharmacy……………10
2.2.1 Benefits for Consumers…………..10
i. Time Saving ……………..10
ii. Cost Savings ………………10
iii. Efficiency……………..11
iv. Personalisation ……………11
v. Range of Choice……………11
2.2.2 Benefits for Corporations…………..11
i. Time Saving ……………..11
ii. Maximise Profit Margin…………11
Figure 2.3: Visualisation Showing Benefits for Corporates…… 12
iii. Benefits for Governments …………12
2.3 Exploration of Key Market Drivers…………..12
2.4 Limitations………………..13

3. Regional Analysis

3.1 Regional Analysis……………… 16
3.1.1 North America…………….. 16
i. US……………… 16
ii. Canada …………….. 16
3.1.2 Latin America ……………… 17
i. Mexico………………. 17
ii. Brazil……………… 17
3.1.3 West Europe…………….. 18
i. Germany ……………… 18
ii. UK……………….. 18
3.1.4 East & Central Europe ……………. 19
i. Poland ………………. 19
ii. Turkey………………. 19
3.1.5 Far East & China…………….. 20
i. China………………. 20
ii. South Korea ……………… 20
3.1.6 Indian Subcontinent……………. 20
i. India……………….. 20
ii. Pakistan……………. 21
3.1.7 Asia Pacific …………….. 21
i. Australia ……………. 21
ii. Philippines …………….. 21
3.1.8 Africa & Middle East ……………. 22
i. Egypt………………. 22
ii. United Arab Emirates ………….. 22

4. Competitor Leaderboard and Vendor Profiles

Table 4.1: Juniper Research Competitor Leaderboard: ePharmacy Vendors Included & Product Portfolio …………… 26
Figure 4.2: Juniper Research Leaderboard: ePharmacy Vendors …. 27
Table 4.3: Juniper Research Leaderboard: ePharmacy Vendors & Positioning .. 27
Table 4.4: Juniper Research Leaderboard Heatmap: ePharmacy Vendors … 28

4.1 ePharmacy – Vendor Profiles …………….29
4.1.1 1mg ………………..29
i. Corporate Information ………….29
ii. Geographical Spread…………….29
iii. Key Clients and Partnerships ………….29
iv. High-Level of Offerings …………..29
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..29
4.1.2 Amazon Pharmacy …………….30
i. Corporate Information ………….30
Table 4.5: Amazon’s Select Financial Information ($bn), FY2019-2021 (FYE 31st December)………………. 30
ii. Geographical Spread…………….30
iii. Key Clients and Partnerships ………….30
iv. High-Level of Offerings …………..30
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..30
4.1.3 Apollo Pharmacy …………….31
i. Corporate Information ………….31
ii. Geographical Spread…………….31
iii. Key Clients and Partnerships ………….31
iv. High-Level of Offerings …………..31
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..31
4.1.4 CVS Pharmacy………………32
i. Corporate Information…………. 32
Table 4.6: CVS Health Corporation’s Select Financial Information ($bn), FY 2019-2021 (FYE 31st December) ……………32
ii. Geographical Spread …………… 32
iii. Key Clients and Partnerships…………. 32
iv. High-level of Offerings………… 32
v. Juniper Research’s View: Key Strengths & Strategic Development
Opportunities ……………. 33
4.1.5 DocMorris ……………… 33
i. Corporate Information…………. 33
Table 4.7: Zur Rose’s Select Financial Information ($bn), FY 2019-2021 (FYE 31st December)………………..33
ii. Geographical Spread …………… 33
iii. Key Clients and Partnerships…………. 33
iv. High-Level View of Offerings……….. 33
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 34
4.1.6 Express Scripts ……………. 34
i. Corporate Information…………. 34
ii. Geographical Spread …………… 34
iii. Key Clients and Partnerships…………. 34
iv. High-level of Offerings………… 35
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 35
4.1.7 Giant Eagle…………….. 35
i. Corporate Information…………. 35
ii. Geographical Spread …………… 35
iii. Key Clients and Partnerships…………. 35
iv. High-Level of Offerings………….. 36
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 36
4.1.8 Lloyds Pharmacy …………….36
i. Corporate Information ………….36
ii. Geographical Spread…………….36
iii. Key Clients and Partnerships ………….36
iv. High-level of Offerings …………36
Figure 4.8: Visualisation of Lloyds Direct App………… 37
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..37
4.1.9 Netmeds………………37
i. Corporate Information ………….37
ii. Geographical Spread…………….37
iii. Key Clients and Partnerships ………….37
iv. High-level of Offerings …………38
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..38
4.1.10 Optum ……………….38
i. Corporate Information ………….38
ii. Geographical Spread…………….38
iii. Key Clients and Partnerships ………….38
iv. High-Level of Offerings …………..38
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..39
4.1.11 Rowlands Pharmacy …………..39
i. Corporate Information ………….39
ii. Geographical Spread…………….39
iii. Key Clients and Partnerships ………….39
iv. High-Level of Offerings …………..39
Figure 4.9: Rowlands Pharmacy Hey Pharmacist……… 40
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..40
4.1.12 The Kroger ………………40
i. Corporate Information…………. 40
Table 4.10: Kroger’s Select Financial Information ($bn), FY2020-2022 (FYE 31st January)…………………40
ii. Geographical Spread …………… 40
iii. Key Clients and Partnerships…………. 41
iv. High-Level of Offerings………….. 41
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 41
4.1.13 Walgreens Boots Alliance ………….. 41
i. Corporate Information…………. 41
Table 4.11: Walgreens Boots Alliance’s Select Financial Information ($bn),
FY2019-2021 (FYE 30th August) …………….42
ii. Geographical Spread …………… 42
iii. Key Clients and Partnerships…………. 42
iv. High-level of Offerings………… 42
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 42
4.1.14 Walmart ……………. 42
i. Corporate Information…………. 42
Table 4.12: Walmart’s Select Financial Information ($bn), FY 2020-2022 (FYE 31st January)…………………43
ii. Geographical Spread …………… 43
iii. Key Clients and Partnerships…………. 43
iv. High-level of Offerings………… 43
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities ……………. 43
4.1.15 Well Pharmacy …………….. 43
i. Corporate Information…………. 43
ii. Geographical Spread …………… 44
iii. Key Clients and Partnerships…………. 44
iv. High-level of Offerings………… 44
v. Juniper Research’s View: Key Strengths & Strategic Development Opportunities……………..44
Table 4.13: Juniper Research Competitor Leaderboard Scoring Criteria…. 46

5. Market Forecasts

5.1 Introduction………………48
5.1.1 ePharmacy Prescription Forecast Methodology ……48
5.1.2 ePharmacy OTC Forecast Methodology ……..48
Figure 5.1: ePharmacy Prescription Revenue Methodology ……. 49
Figure 5.2: ePharmacy OTC Revenue Methodology……… 50
5.1.3 Total ePharmacy Transactions ………..51
Figure & Table 5.3: Total ePharmacy Transactions (m), Split by 8 Key Regions, 2022-2027………………. 51
Table 5.4: Total ePharmacy Transactions, Split by Prescription and OTC Medication ………………… 51
5.1.4 Total ePharmacy Transaction Value…………52
Figure & Table 5.5: Total ePharmacy Transaction Value ($m), Split by 8 Key Regions, 2022-2027 ……………… 52
Table 5.6: Total ePharmacy Transaction Value, Split by Prescription and OTC Medication ………………… 52
5.1.5 Total ePharmacy Revenue………….54
Figure & Table 5.7: Total ePharmacy Revenue ($m), Split by 8 Key Regions, 2022-2027……………….. 54
Table 5.8: Total ePharmacy Revenue ($m), Split by Prescription and OTC Medication ………………… 54


    주문/문의폼

    • 리포트 제목은 자동으로 입력됩니다.

    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com